Baird analyst Joel Beatty lowered the firm’s price target on Calidi to $2 from $4.50 and keeps an Outperform rating on the shares. The firm continues to view the company as having a differentiated oncology platform, which uses allogeneic stem cells to protect, amplify, deliver and potentiate oncolytic viruses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi Biotherapeutics Clarifies Disclosure’s Legal Standing
- Calidi Biotherapeutics Shares Informative Investor Presentation Slides
- Calidi Biotherapeutics Bolsters Finance with Strategic Offering
- Calidi $6.1M public offering at 40c per share
- Calidi presents new data on mechanism of action for its therapies at AACR